Omissions rollback.

We have randomized data that it’s relatively safe to omit adjuvant radiation in older women with early stage breast cancer who take endocrine therapy (ET). What’s happened since then? Radiation regimens have gotten much shorter, endocrine therapy duration has gotten much longer, and population data has shown us that fewer than half of patients actually comply with their intended endocrine therapy regimen. So, why not consider omitting the ET? We’ve recently seen a Markov model simulating such a randomization, and here we have data from the national cancer database (NCDB) comparing survival outcomes for either radiation alone or ET alone after lumpectomy. Included cases had to be 70 or older with hormone-receptor positive, HER2 negative, T1 breast cancer. Among the nearly 3000 cases, two thirds received ET alone while the other third received radiation alone. At 5 years, there was no difference in the overall survival rate between groups. TBL: Despite the limitations of NCDB analyses, there again appears to be no difference in outcomes when omitting adjuvant endocrine therapy in favor of breast radiation in older women with early stage breast cancer. | Buszek, Int J Radiat Oncol Biol Phys 2019

Comments

  1. like this post because it contains a lot of useful information to read, maybe everyone will like me. I hope this post of yours will be more appreciated by it really excellent, i enjoyed it, thanks for posting it.
    jogos 4 school
    friv for school free Games
    a10 games

    ReplyDelete

Post a Comment

Popular Posts